A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
Authors:
- 8 December 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 17 (2) , 139-152
Abstract
Introduction: In most cases, metastatic breast cancer remains an incurable disease. A PIK3CA mutation is detected in 30–40% of all hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancers. PIK3CA activating mutations have been linked to endocrine resistance. PI3K inhibitors therefore offer promising new therapeutic options for this disease. Areas covered: This review discusses the pharmacologic properties, preclinical development, clinical efficacy, and safety profile of alpelisib, a PI3K inhibitor indicated in HR+/HER2– PIK3CA-mutated advanced breast cancer, describing current therapeutic indication and open questions. Expert opinion: Following results of the SOLAR-1 trial, alpelisib became the first PI3K inhibitor approved by the U.S. Food and Drug Administration, in combination with fulvestrant, for postmenopausal women and men with HR+/HER2– PIK3CA-mutated advanced breast cancer following progression on or after an endocrine-based regimen. This trial showed a substantial improvement in progression-free survival. However, given the side effects of alpelisib, the treatment decision should follow a thorough benefit-risk assessment. The BYLieve trial suggests alpelisib-fulvestrant benefit after progression on CDK 4/6 inhibitors. The identification of patients that are likely to benefit the most from PI3K inhibitors is still eagerly sought.Keywords
This publication has 94 references indexed in Scilit:
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral BloodClinical Cancer Research, 2012
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast CancerJournal of Clinical Oncology, 2011
- Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Research, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancerJournal of Clinical Investigation, 2010
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006